Adaptive biotechnologies chief commercial officer sells $32,265 in shares.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) saw one of its key executives, Chief Commercial Officer Susan Bobulsky, sell 1,195 shares of the company's common stock on September 15, 2026. The sale, conducted under a Rule 10b5-1 trading plan, totaled $32,265, with each share priced at $27. Following the transaction, the stock price has since risen to $28.55, nearing its 52-week high of $28.72, indicating a 107% return over the past year.
Despite this, analysts at InvestingPro suggest that the stock may be overvalued at its current price. The transaction was disclosed in a report from Investing.com, which also covered Adaptive Biotechnologies' second-quarter financial results, showing an adjusted loss of $0.25 per share, exceeding the estimated $0.14 loss. However, the company reported revenue of $71.6 million, a 22% increase from the previous year, and noted strong performance in clonoSEQ volumes and MRD test franchise growth.
Analysts at Guggenheim and BTIG have raised their price targets for the stock to $25, highlighting the company's positive trends in revenue and market engagement.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
